リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Iatrogenic risk of osteonecrosis of the jaw? Bone substitutes for dental implants: a warning from Japan」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Iatrogenic risk of osteonecrosis of the jaw? Bone substitutes for dental implants: a warning from Japan

Hibi, Hideharu 名古屋大学

2020.02

概要

Commercial bone substitutes that are widely used for bone augmentation for dental implants are predisposing factors in the development of osteonecrosis of the jaw (ONJ), overlooking this situation may lead to serious problems. Most of these materials are supplied as inorganic porous granules of calcium phosphate, which have characteristics that exceed the bone resorption ability of normal osteoclasts; therefore, they can be equally regarded as existing antiresorptive necrotic bony granules in the body, i.e., micro-ONJs. In addition, because dental implants directly contact the surrounding bone without the periodontium with immunoprotective functions, the mucosal penetration of the dental implant itself predisposes the underlying bone to the risk of infection, latent osteomyelitis, and ONJ. Therefore, the remaining porous granules surrounding the dental implant pose an additional iatrogenic risk, even though the tissue may appear superficially healthy. In an aging society, an individual who was systemically healthy at the time of implantation with bone augmentation could develop osteoporosis or cancer bone metastasis later in life. ONJ can occur more easily if an antiresorptive agent such as bisphosphonates or denosumab is administered without sufficiently recognizing an intraoral situation. If the latent risk is known in advance, the selection or use of medicines could be restricted. Such restrictions can result in other crucial issues that are beyond the discretion of the dentists; however, dentists have not been warned about such possibilities. The use of antiresorptive agents and bone substitutes for dental implants should be reconsidered to avoid numerous adverse events such as ONJ.

この論文で使われている画像

参考文献

1) 2) 3) 4) 5) 6) Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a

systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23. doi: org/10.1002/

jbmr.2405.

iData Research. Market Reports, Dental bone graft substitutes. https://idataresearch.com/product-category/

dental/dental-bone-graft-substitutes/. Accessed July 15, 2019.

Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fasttrack process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2006;9(12):1166–1172. doi:

org/10.1016/S1470-2045(08)70305-X.

Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper

on medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–1956.

doi: org/10.1016/j.joms.2014.04.031.

Yoneda T, Hagino H, Sugimoto T, et al. Antiresorptive agent-related osteonecrosis of the jaw: position paper

2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35(1):6–19.

doi: org/10.1007/s00774-016-0810-7.

Pogrel MA, Ruggiero SL. Previously successful dental implants can fail when patients commence

anti-resorptive therapy: a case series. Int J Oral Maxillofac Surg. 2018;47(2):220–222. doi: org/10.1016/j.

ijom.2017.07.012.

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る